Recombinant coagulation factor VIII
This page covers all Recombinant coagulation factor VIII drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Coagulation factor VIII, Coagulation Factor VIII (antihemophilic factor), Fibrinogen (Factor I).
Targets
Coagulation factor VIII · Coagulation Factor VIII (antihemophilic factor) · Fibrinogen (Factor I) · Factor IX (coagulation factor IX) · Factor IXa and Factor X (intrinsic tenase complex) · Coagulation Factor VIII · Coagulation factor VIII (intrinsic tenase complex) · Fibrinogen · Coagulation Factor IX (FIX) · Factor IX (coagulation cascade)
Marketed (25)
- Moroctocog alfa (AF-CC) · Pfizer · Hematology
Moroctocog alfa is a recombinant human coagulation factor VIII that replaces deficient or dysfunctional factor VIII to restore blood clotting ability in hemophilia A patients. - Coagulation Factor VIII · Beijing Children's Hospital · Hematology
Coagulation Factor VIII replaces deficient or dysfunctional clotting factor VIII to restore the intrinsic coagulation pathway and enable normal blood clot formation. - Fibrinogen Concentrate Human · IRCCS Policlinico S. Donato · Hematology
Fibrinogen Concentrate Human replaces or supplements deficient fibrinogen to restore normal blood clotting function. - Albutrepenonacog Alfa 1 UNT [IDELVION] · National Taiwan University Hospital · Hematology
Albutrepenonacog alfa is a recombinant fusion protein that replaces deficient Factor IX (Christmas factor) to restore blood coagulation in hemophilia B patients. - efanesoctacog alpha · Versiti Blood Health · Hematology
Efanesoctacog alpha is a recombinant fusion protein that bridges Factor IXa and Factor X to restore the intrinsic tenase complex activity in patients with hemophilia B. - Recombinant Human Coagulation FVIII · Sinocelltech Ltd. · Hematology
Recombinant human coagulation factor VIII replaces deficient or dysfunctional Factor VIII to restore the intrinsic coagulation pathway and enable normal blood clot formation. - Efmoroctocog Alfa Injection [Eloctate] · The League of Clinical Research, Russia · Hematology
Efmoroctocog alfa is a recombinant human coagulation factor VIII fused to human serum albumin, which replaces deficient clotting factor VIII to restore hemostasis in hemophilia A patients. - Bovine thrombin · Instituto Grifols, S.A. · Hematology / Hemostasis
Bovine thrombin is a serine protease that directly converts fibrinogen to fibrin, promoting blood clotting and hemostasis. - RIXUBIS: On-Demand · Baxalta now part of Shire · Hematology
RIXUBIS is a recombinant Factor IX that replaces deficient or dysfunctional clotting factor IX to restore blood coagulation in patients with hemophilia B. - OBIZUR · Baxalta now part of Shire · Hematology
OBIZUR is a recombinant human Factor VIII that replaces deficient or dysfunctional Factor VIII to restore blood clotting ability in patients with hemophilia A. - Fibrinogen · Rigshospitalet, Denmark · Other
- FIX · Bioverativ Therapeutics Inc. · Hematology
FIX is a recombinant coagulation Factor IX that replaces deficient or dysfunctional Factor IX to restore the intrinsic coagulation pathway in patients with hemophilia B. - TachoSil · Corza Medical GmbH · Cardiovascular
TachoSil works by activating the coagulation cascade to form a blood clot. - Fibrinogen + PCC · University Health Network, Toronto · Hematology / Critical Care / Hemostasis
This combination replaces depleted fibrinogen and restores multiple clotting factors simultaneously to correct severe coagulopathy and promote hemostasis. - RIXUBIS: Prophylaxis · Baxalta now part of Shire · Hematology
Rixubis is a recombinant Factor IX (prothrombin complex component) that replaces deficient clotting factor to restore the intrinsic coagulation pathway. - Factor IX recovery · Wyeth is now a wholly owned subsidiary of Pfizer · Hematology
Factor IX recovery refers to the measurement of how much functional Factor IX (a blood clotting protein) is present in the bloodstream after administration of a Factor IX replacement product. - Prothrombin Complex Concentrate, Human · SHI Jia · Hematology / Hemostasis
Prothrombin Complex Concentrate replaces deficient vitamin K-dependent clotting factors (II, VII, IX, X) to restore coagulation cascade function and reverse anticoagulation. - Kogenate (BAY 14-2222) · Bayer · Hematology
Kogenate is a recombinant human coagulation factor VIII that replaces deficient or dysfunctional factor VIII to restore blood clotting ability in hemophilia A patients. - OctaplasLG® · Rigshospitalet, Denmark · Hematology; Hemostasis
OctaplasLG® is a liquid plasma product that replaces multiple coagulation factors and other plasma proteins to restore hemostatic function in patients with coagulation deficiencies. - von Willebrand factor · National Center for Research Resources (NCRR) · Hematology
Von Willebrand factor (vWF) is a blood glycoprotein that mediates platelet adhesion to damaged blood vessel walls and serves as a carrier protein for clotting factor VIII. - Plasma-derived FVIII/VWF concentrate · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Hematology
This plasma-derived concentrate replaces deficient Factor VIII (FVIII) and von Willebrand Factor (VWF) to restore blood clotting ability in patients with hemophilia A or von Willebrand disease. - Kogenate (BAY14-2222) · Bayer · Hematology
Kogenate is a recombinant human coagulation factor VIII that replaces deficient or dysfunctional factor VIII to restore blood clotting ability in hemophilia A patients. - Intravenous infusions of Xyntha · Pfizer · Hematology
Xyntha is a recombinant coagulation factor VIII that replaces deficient or dysfunctional factor VIII to restore blood clotting ability in hemophilia A patients. - Recombinant Von Willebrand factor · Nicoletta C Machin · Hematology
Recombinant von Willebrand factor replaces or supplements the natural von Willebrand factor protein to restore platelet adhesion and coagulation factor VIII binding. - Eptacog alfa (NovoSeven) · Novo Nordisk A/S · Hematology
Eptacog alfa is a recombinant Factor VIIa that bypasses upstream coagulation defects by directly activating Factor X on the tissue factor pathway to initiate thrombin generation and hemostasis.
Phase 3 pipeline (13)
- FVIII (PK subgroup only) · Bioverativ Therapeutics Inc. · Hematology
FVIII is a recombinant coagulation factor VIII that replaces deficient or dysfunctional clotting factor to restore hemostasis in hemophilia A patients. - human VWF/FVIII concentrate · Octapharma · Hematology
Human VWF/FVIII concentrate replaces clotting factors in the blood to prevent or control bleeding episodes in patients with hemophilia A. - Eptacog alfa, biosimilar · AryoGen Pharmed Co. · Hematology
Eptacog alfa is a recombinant activated Factor VII that bypasses upstream coagulation defects to directly activate Factor X and initiate thrombin generation for hemostasis. - BE1116 · CSL Behring · Hematology
BE1116 is a recombinant human albumin-von Willebrand factor (VWF) fusion protein that replaces or augments deficient VWF function in von Willebrand disease. - Turoctocog alfa pegol (N8-GP) · Novo Nordisk A/S · Hematology
Turoctocog alfa pegol is a recombinant human coagulation factor VIII with extended half-life achieved through PEGylation, which replaces deficient clotting factor in hemophilia A patients. - FXIII Concentrate (Human) · CSL Behring · Hematology
FXIII Concentrate replaces deficient coagulation Factor XIII to restore normal blood clot cross-linking and stabilization. - Recombinant Activated Factor VII · Hoffmann-La Roche · Hematology
Recombinant Activated Factor VII (rFVIIa) directly activates the extrinsic coagulation pathway to promote thrombin generation and hemostasis. - rFIX-R · Wyeth is now a wholly owned subsidiary of Pfizer · Hematology
rFIX-R is a recombinant coagulation factor IX used to treat bleeding episodes in patients with hemophilia B. - rThrombin · ZymoGenetics · Hematology
rThrombin is a recombinant human thrombin that directly converts fibrinogen to fibrin to promote blood clotting and hemostasis. - factor concentrates · Genzyme, a Sanofi Company · Hematology
Factor concentrates replace or supplement deficient clotting factors to restore hemostatic function in patients with bleeding disorders. - rFIX · Wyeth is now a wholly owned subsidiary of Pfizer · Hematology
rFIX is a recombinant human coagulation factor IX that replaces deficient or dysfunctional Factor IX to restore blood clotting ability in hemophilia B patients. - BAX 326 · Baxalta now part of Shire · Hematology
BAX 326 is a recombinant human coagulation factor VIII designed to treat hemophilia A by replacing deficient or dysfunctional factor VIII. - Factor VIII (FVIII) · Hoffmann-La Roche · Hematology
Factor VIII is a clotting factor that replaces deficient or dysfunctional coagulation factor VIII to restore blood clotting ability in hemophilia A patients.
Phase 2 pipeline (4)
- FVIII products · Bayer · Hematology
FVIII products replace or supplement the missing or defective clotting factor VIII in the blood to help the blood to clot normally. - Freeze-dried Human Protein C Concentrate · Takeda · Cardiovascular
Freeze-dried Human Protein C Concentrate works by replacing a clotting factor in the blood to prevent excessive clotting. - Activated Prothrombin Complex Concentrate · Hoffmann-La Roche · Hematology
Activated Prothrombin Complex Concentrate works by replacing clotting factors to help the blood to clot. - FVIII Replacement · Hoffmann-La Roche · Rare Disease
Recombinant FVIII replacement to correct FVIII deficiency
Patent intelligence
- coagulation factor patent landscape — aggregated cliff calendar, attackable patents, originator estates